Home  |  About us  |  Editorial board  |  Current issue  |  Archives  |  Submit article  |  Instructions  |  Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 169Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
ORIGINAL ARTICLE
Year : 2014  |  Volume : 5  |  Issue : 2  |  Page : 71-74

Effects of botropase on clotting factors in healthy human volunteers


1 Department of Pharmacology, Kasturba Medical College, Manipal University, Mangalore, Karnataka, India
2 Department of Medicine, Kasturba Medical College, Manipal University, Mangalore, Karnataka, India

Correspondence Address:
Mukta N Chowta
Department of Pharmacology, Kasturba Medical College, Manipal University, Mangalore - 575 001, Karnataka
India
Login to access the Email id

Source of Support: Juggat Pharma Ltd., Bangalore, India., Conflict of Interest: None


DOI: 10.4103/2229-3485.128024

Rights and Permissions

Objective: To evaluate the effects of botropase on various clotting factors in human volunteers. Materials and Methods: It was a prospective open label study conducted on human healthy volunteers. After the baseline screening, subjects fulfilling inclusion criteria were enrolled. On the study day, 1 ml of botropase was administered intravenously and after an hour same dose of botropase (1 ml) was given by intramuscular (IM) route. The efficacy and safety parameters were monitored up to 72 h from the time of intravenous (IV) administration. Results: A total of 15 volunteers, belonging to 24-35 years of age were included in the study. Botropase significantly reduced the plasma level of fibrinogen and fibrin degradation products after 5 min of IV administration (P < 0.05). In addition, factor X was observed to reduce constantly by botropase administration suggesting enhanced turnover between 5 and 20 min of IV administration. Although botropase reduced clotting and bleeding time in all the volunteers, the data remains to be statistically insignificant. Conclusion: Present study demonstrated the safety and efficacy of botropase in human healthy volunteers. The study has shown that it is a factor X activator and reduces effectively clotting and bleeding time.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed9305    
    Printed44    
    Emailed0    
    PDF Downloaded326    
    Comments [Add]    
    Cited by others 3    

Recommend this journal